Design of therapeutics and therapeutics

• US 20060018911A1
• Filed: 01/10/2005
• Published: 01/26/2006
• Est. Priority Date: 01/12/2004
• Status: Abandoned Application

• Current Assignee: Pointilliste, Inc.
• Original Assignee: Pointilliste, Inc.
• Inventors: Levy, Ronald, Ault-Riche, Dana
• Application Number:
  US11/032,773
• Publication Number:
  US 20060018911A1
• Time in Patent Office: Days
• US Class Current: 424/178.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 39/39566 against immunoglobulins, e.g. anti-idiotypic antibodies
• CPC Class Codes: A61K 47/665 the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
• CPC Class Codes: A61K 47/6897 Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 16/4241 against anti-human or anti-animal Ig
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Therapeutic complexes and components of therapeutic complexes are provided herein. Also provided are methods of preparing therapeutic complexes and methods of administering therapeutic complexes.

Claims

1. A therapeutic complex, selected from among:

(a) a therapeutic complex, comprising;

a targeting domain and an effector molecule, wherein;

the targeting domain specifically binds to a subject-specific target;

the effector molecule renders the resulting therapeutic complex biologically effective;

the targeting domain and effector molecule are linked via the specific interaction of a binding partner and a capture agent;

the binding partner is conjugated to the targeting domain; and

the capture agent is conjugated to the effector molecule;

(b) therapeutic complex, comprising;

a targeting domain and an effector molecule, wherein;

the targeting domain specifically binds to a target;

the effector molecule is a polypeptide and renders the resulting therapeutic complex biologically effective;

the targeting domain and effector molecule are linked via the specific interaction of a binding partner and a capture agent;

the binding partner is a polypeptide between 5 and 100 amino acids in length;

the binding partner is conjugated to the targeting domain;

the capture agent is conjugated to the effector molecule; and

(c) a therapeutic complex, comprising;

a targeting domain and an effector molecule, wherein;

the targeting domain specifically binds to a target;

the effector molecule renders the resulting therapeutic complex biologically effective, wherein the biological effect of the therapeutic complex is selected from the group consisting of an immunomodulatory effect and an apoptotic effect;

the targeting domain and effector molecule are linked via the specific interaction of a binding partner and a capture agent;

the binding partner is conjugated to the targeting domain; and

the capture agent is conjugated to the effector molecule.

2. A therapeutic complex of claim 1 that is represented by the formula:

(TR)_r-(L1)_s-(B1)_t-(B2)_x-(L2)_y-(E)_z, wherein;

TR is a targeting domain;

E is an effector molecule;

r and z represent the number of TR and E moieties present in a complex, respectively;

B1 and B2 are binding partners and capture agents, respectively;

t and x represent the number of B 1 and B2 moieties present in a complex, respectively;

L1 and L2 are optional linkers;

s and y represent the number of linker moieties L1 and L2 in a complex, respectively, wherein each of s and y is selected independently and each is zero or an integer from 1 to n and n is any number of moieties that permit the complex to form and carry out its intended effect;

“

-”

represents an interaction between each component such that the resulting therapeutic complex is sufficiently stable upon formation to achieve the therapeutic effect;

each of r, t, x, and z is selected independently and each is an integer from 1 to n, where n is any number of moieties that permit the complex to form such that the resulting complex has an intended therapeutic activity.

3. A therapeutic complex of claim 1, wherein the effector is not a radiolabel.

4. The therapeutic complex of claim 1(b), wherein the polypeptide binding partner is a polypeptide of a length of amino acids selected from the group consisting of 5 to 50 amino acids, 5 to 20 amino acids, 5 to 12 amino acids, and 5 to 8 amino acids.

5. A therapeutic complex of claim 1, wherein the targeting domain is a polypeptide.

6. A therapeutic complex of claim 1, wherein the targeting domain is an antibody or fragment thereof.

7. The therapeutic complex of claim 6, wherein the antibody is a single chain antibody (scFv).

8. The therapeutic complex of claim 7, wherein the antibody or fragment thereof is humanized.

9. The therapeutic complex of claim 1, wherein the targeting domain comprises at least one variable region of an antibody.

10. The therapeutic complex of claim 1, wherein the targeting domain comprises one or more CDRs of an antibody.

11. The therapeutic complex of claim 5, wherein the polypeptide targeting domain is selected from the group consisting of a cell surface receptor, a ligand for a receptor, a cell surface antigen, and an adhesion molecule.

12. The therapeutic complex of claim 1, wherein the targeting domain binds to a cell.

13. The therapeutic complex of claim 12, wherein the cell is a B cell or a T cell.

14. The therapeutic complex of claim 12, wherein the cell is selected from a tumor cell, an antibody-secreting cell, an antigen presenting cell, a lymphoma cell and a cytokine-secreting cell.

15. The therapeutic complex of claim 1, wherein the targeting domain binds to a cell surface molecule.

16. The therapeutic complex of claim 15, wherein the cell surface molecule is selected from the group consisting of a receptor, an antibody, an antigen, a ligand for a receptor and an adhesion molecule.

17. The therapeutic complex of claim 1, wherein the targeting domain binds to a secreted molecule, an antibody, a cytokine, or a pathogen.

18. The therapeutic complex of claim 17, wherein the antibody is an auto-antibody or an anti-idiotype antibody.

19. The therapeutic complex of claim 17, wherein the pathogen is a virus or a parasite.

20. The therapeutic complex of claim 1, wherein the binding partner is a polypeptide binding partner.

21. The therapeutic complex of claim 20, wherein the polypeptide binding partner and targeting domain comprises a fusion protein.

22. The therapeutic complex of claim 20, wherein the polypeptide binding partner is selected from the group consisting of an antibody, an antibody fragment, an antigen, an epitope for an antibody, a receptor ligand and a receptor.

23. The therapeutic complex of claim 1, wherein the targeting domain and binding partner are linked directly or indirectly through a linker via covalent linkage.

24. The therapeutic complex of claim 1, wherein the capture agent and effector are linked directly or indirectly through a linker via non-covalent linkage.

25. The therapeutic complex of claim 1, wherein the capture agent and the binding partner are not constant domains of an antibody.

26. The therapeutic complex of claim 1, wherein the effector comprises a polypeptide.

27. The therapeutic complex of claim 26, wherein:

the effector comprises an antibody or fragment thereof.

28. The therapeutic complex of claim 27, wherein the antibody or fragment thereof is humanized.

29. The therapeutic complex of claim 1, wherein the effector interacts with an Fc receptor.

30. The therapeutic complex of claim 29, wherein the effector comprises an Fc domain.

31. The therapeutic complex of claim 30, wherein the Fc domain amino acid sequence comprises an Fc domain sequence from a murine IgG2a, a human IgG1 or a human IgG3 antibody.

32. The therapeutic complex of claim 1, wherein the effector is a cytokine.

33. The therapeutic complex of claim 1, wherein the effector and the capture agent comprise a fusion protein.

34. The therapeutic complex of claim 1, wherein the effector is selected from the group consisting of an enzyme, a receptor, a ligand for a receptor, and an inhibitor of a receptor.

35. The therapeutic complex of claim 1, wherein the biological effect is selected from among an immunomodulatory effect, receptor binding, receptor inhibition, enzymatic modification, and enzymatic degradation.

36. The therapeutic complex of claims 35, wherein the immunomodulatory effect is selected from the group consisting of neutralization, immunosuppression, clearance, modulation of cytokine expression or secretion, modulation of T cell activation, modulation of immune cell proliferation, complement activation, antibody-dependent cellular cytotoxicity (ADCC), and opsonization.

37. The therapeutic complex of claim 1, wherein binding between the capture agent and the binding partner is effected via hydrophobic interaction.

38. The therapeutic complex of claim 1, wherein components of the complex are cross-linked or chemically conjugated.

39. A pharmaceutical composition, comprising a therapeutic complex of claim 1.

40. The pharmaceutical composition of claim 39, wherein the biological effect comprises a therapeutic effect.

41. A method of treating a disease or condition, comprising:

administering a pharmaceutical composition of claim 39.

42. The method of claim 41, wherein the composition comprises a therapeutic complex designed for personalized treatment.

43. The method of claim 41, wherein the disease is selected from B cell-mediated diseases, an autoimmune disease and T cell-mediated diseases.

44. The method of claim 41, wherein the disease or condition is selected from cancers, inflammatory diseases, autoimmune diseases, infectious diseases, neurodegenerative diseases, and ophthalmic diseases.

45. The method of claim 41, wherein the disease or condition is selected from non-Hodgkin'"'"'s lymphoma, rheumatoid arthritis, lupus, multiple sclerosis, melanoma, a posterior intraocular inflammation, pathogen and virus infection.

46. The method of claim 41, wherein the targeting domain and the effector are administered as a complex, or wherein the targeting domain and the effector are administered sequentially, simultaneously or intermittently.

47. The method of claim 41, wherein:

the targeting domain and effector are administered separately; and

either

one or more doses of the targeting domain is(are) administered prior to administration of a therapeutic complex also comprising the targeting domain;

or

one or more doses of the effector prior is (are) administered prior to administration of a therapeutic complex comprising the effector.

48. A method of preparing a therapeutic complex of claim 1, comprising:

contacting a targeting domain and an effector molecule under conditions, whereby a complex forms, wherein,

the targeting domain specifically binds to a target;

the effector molecule renders the resulting therapeutic complex biologically effective;

the targeting domain and effector molecule are linked via the specific interaction of a binding partner and a capture agent;

the binding partner is conjugated to the targeting domain; and

the capture agent is conjugated to the effector molecule.

49. The method of claim 48, wherein the targeting domain and effector molecule are contacted in vitro.

50. The method of claim 48, wherein the complex is cross-linked or chemically conjugated after formation.

51. The method of claim 50, further comprising the step of cross-linking the binding partner and capture agent after complex formation.

52. The method of claim 48, further comprising isolating the complex after formation.

53. The method of claim 48, wherein the targeting domain and effector molecule are contacted in vivo in a subject after separate administration of each to the subject.

54. The method of claim 48, wherein the targeting domain and the effector molecule are expressed in a cell, wherein the complex forms.

55. The method of claim 48, wherein the targeting domain is subject-specific.

56. The method of claim 48, wherein the effector molecule is a polypeptide.

57. The method of claim 48, wherein the effector molecule confers an immunomodulatory effect.

58. A method of rendering an antibody or antibody fragment therapeutically effective, comprising:

preparing a therapeutic by combining a targeting domain that comprises an antibody or fragment thereof with an effector molecule via the specific interaction of a binding partner and capture agent to form a therapeutic complex of claim 1, whereby the complex is therapeutically effective, wherein the complex comprises;

a targeting domain comprising an antibody or antibody fragment that specifically binds to a target;

an effector molecule;

the effector molecule renders the resulting complex therapeutically effective;

the targeting domain and effector molecule are linked via the specific interaction of a binding partner and a capture agent;

the binding partner is conjugated to the targeting domain;

the capture agent is conjugated to the effector molecule.

59. A method of rendering a target-specific polypeptide therapeutically effective, comprising:

preparing a therapeutic complex by combining a targeting domain with an effector molecule via the specific interaction of a binding partner and capture agent, to form a therapeutic complex of claim 1, wherein the complex comprises;

a targeting domain comprising a polypeptide, wherein the polypeptide specifically binds to a target;

an effector molecule, wherein;

the effector molecule renders the resulting complex therapeutically effective;

the targeting domain and effector molecule are linked via the specific interaction of a binding partner and a capture agent;

the binding partner is conjugated to the targeting domain;

the binding partner is a polypeptide of length sufficient to specifically interact with a capture agent and is less than about 100 amino acids;

the capture agent is conjugated to the effector molecule.

60. The method of claim 59, wherein the binding partner contains 5 to 50 amino acids, 5 to 30 amino acids, 5 to 20 amino acids, 5 to 12 amino acids or 5 to 8 amino acids.

61. The method of claim 59, wherein the polypeptide targeting domain comprises an antibody or an antibody fragment.

62. The method of claim 61, wherein the antibody or antibody fragment is selected from the group consisting of a single chain antibody (scFv), an anti-idiotype antibody, a variable region, a fragment of a variable region sufficient to bind to another molecule, a CDR, a Fab, a F(ab)₂, and an Fv.

63. The method of claim 61, wherein:

the antibody or antibody fragment binds to a cell-surface molecule;

or

the antibody or antibody fragment binds to a subject-specific target.

64. A method of screening test molecules to identify effectors for use in the therapeutic complexes of claim 1, comprising:

a) preparing a complex by combining;

a targeting domain comprising an antibody or antibody fragment, wherein the antibody or antibody fragment specifically binds to a target; and

a candidate effector molecule, wherein;

the targeting molecule and candidate effector molecule are linked via the specific interaction of a binding partner and a capture agent;

the binding partner is conjugated to the targeting domain; and

the capture agent is conjugated to the candidate effector molecule;

b) administering the complex to a subject; and

c) detecting an effect on the subject to thereby identify an effector molecule.

65. A method of screening test molecules to identify targeting domains for use in the therapeutic complexes of claim 1, comprising:

a) generating a complex, by combining;

a candidate targeting domain comprising an antibody or antibody fragment;

an effector molecule, wherein;

the effector molecule renders the resulting complex biologically effective;

the candidate targeting domain and effector molecule are linked via the specific interaction of a binding partner and a capture agent;

the binding partner is conjugated to the candidate targeting domain; and

the capture agent is conjugated to the effector molecule;

b) administering the complex to a subject; and

c) detecting a therapeutic effect of the complex on the subject to thereby identify a targeting domain.

66. A therapeutic complex of claim 1, wherein the specific interaction of the binding partner and capture agent is non-covalent.

67. The therapeutic complex of claim 66, wherein the non-covalent linkages are selected from among hydrogen bonding, hydrophobic bonds, Van der Waals interactions and combinations thereof.

68. A therapeutic complex, comprising:

a targeting domain and an effector molecule, wherein;

the targeting domain specifically binds to a target;

the effector molecule renders the resulting therapeutic complex biologically effective;

the targeting domain and effector molecule are linked via the specific interaction of a binding partner and a capture agent;

the binding partner is conjugated to the targeting domain;

the capture agent is conjugated to the effector molecule; and

the capture agent comprises at least one variable domain of an antibody or a portion thereof sufficient to specifically bind to the binding partner.

69. The therapeutic complex of claim 68, wherein the effector molecule and capture agent comprise an antibody or antibody fragment or antibody complex.

70. The therapeutic complex of claim 69, wherein the antibody, antibody fragment or antibody in the complex is selected from the group consisting of rituximab, trastuzumab, tositumomab, ibritumomab, alemtuzumab, infliximab, CDP-571, edrecolomab, muromab-CD3, daclizumab, omalizumab, cetuximab and bevacizumab and antibody fragments thereof.

71. The therapeutic complex of claim 68, wherein the targeting domain specifically binds to a subject-specific target.

72. The therapeutic complex of claim 68, wherein the effector molecule binds to a first target that is the same as the target of the targeting domain in the therapeutic complex.

73. The therapeutic complex of claim 68, wherein the effector molecule is selected from among antibodies, immunotoxins and antibody conjugates.

74. The therapeutic complex of claim 68, wherein the effector molecule binds to a first target that is different from the target of the targeting domain in the therapeutic complex.

75. The therapeutic complex of claim 68, wherein the effector molecule binds to the first target in the absence of the complex, and binding by the effector molecule to the first target is altered or reduced when the effector molecule is part of the therapeutic complex.

76. The therapeutic complex of claim 68, wherein the first target is different from the target of the therapeutic complex, whereby the therapeutic complex binds to either or both targets.

77. The therapeutic complex of claim 76, wherein the different targets occur on the same cell, tissue or molecule.